Pre-Conditioning with IFN-γ and Hypoxia Enhances the Angiogenic Potential of IPSC-Derived MSC Secretome

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Mar 25

PMID 35326438

Authors

Suya Wang

Felix Umrath

Wanjing Cen

Antonio Jose Salgado

Siegmar Reinert

Dorothea Alexander

Affiliations

Soon will be listed here.

Abstract

Induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (iMSCs) represent a promising source of progenitor cells for approaches in the field of bone regeneration. Bone formation is a multi-step process in which osteogenesis and angiogenesis are both involved. Many reports show that the secretome of mesenchymal stromal stem cells (MSCs) influences the microenvironment upon injury, promoting cytoprotection, angiogenesis, and tissue repair of the damaged area. However, the effects of iPSC-derived MSCs secretome on angiogenesis have seldom been investigated. In the present study, the angiogenic properties of IFN-γ pre-conditioned iMSC secretomes were analyzed. We detected a higher expression of the pro-angiogenic genes and proteins of iMSCs and their secretome under IFN-γ and hypoxic stimulation (IFN-H). Tube formation and wound healing assays revealed a higher angiogenic potential of HUVECs in the presence of IFN-γ conditioned iMSC secretome. Sprouting assays demonstrated that within Coll/HA scaffolds, HUVECs spheroids formed significantly more and longer sprouts in the presence of IFN-γ conditioned iMSC secretome. Through gene expression analyses, pro-angiogenic genes (FLT-1, KDR, MET, TIMP-1, HIF-1α, IL-8, and VCAM-1) in HUVECs showed a significant up-regulation and down-regulation of two anti-angiogenic genes (TIMP-4 and IGFBP-1) compared to the data obtained in the other groups. Our results demonstrate that the iMSC secretome, pre-conditioned under inflammatory and hypoxic conditions, induced the highest angiogenic properties of HUVECs. We conclude that pre-activated iMSCs enhance their efficacy and represent a suitable cell source for collagen/hydroxyapatite with angiogenic properties.

Citing Articles

Hypoxia-induced PD-L1 expression and modulation of muscle stem cell allograft rejection.

Raiten J, Abd G, Handelsman S, Patel H, Ku J, Parsons A Front Pharmacol. 2024; 15:1471563.

PMID: 39555101 PMC: 11564730. DOI: 10.3389/fphar.2024.1471563.

The VEGF-Mediated Cytoprotective Ability of MIF-Licensed Mesenchymal Stromal Cells in House Dust Mite-Induced Epithelial Damage.

Dunbar H, Hawthorne I, Tunstead C, Dunlop M, Volkova E, Weiss D Eur J Immunol. 2024; 55(1):e202451205.

PMID: 39502000 PMC: 11739667. DOI: 10.1002/eji.202451205.

The application potential of iMSCs and iMSC-EVs in diseases.

Zhou X, Liu J, Wu F, Mao J, Wang Y, Zhu J Front Bioeng Biotechnol. 2024; 12:1434465.

PMID: 39135947 PMC: 11317264. DOI: 10.3389/fbioe.2024.1434465.

Secretome from iPSC-derived MSCs exerts proangiogenic and immunosuppressive effects to alleviate radiation-induced vascular endothelial cell damage.

Gupta K, Perkerson 3rd R, Parsons T, Angom R, Amerna D, Burgess J Stem Cell Res Ther. 2024; 15(1):230.

PMID: 39075600 PMC: 11287895. DOI: 10.1186/s13287-024-03847-5.

The impact of hypoxia preconditioning on mesenchymal stem cells performance in hypertensive kidney disease.

Sohi G, Farooqui N, Mohan A, Rajagopalan K, Xing L, Zhu X Stem Cell Res Ther. 2024; 15(1):162.

PMID: 38853239 PMC: 11163800. DOI: 10.1186/s13287-024-03778-1.

References

Frobel J, Hemeda H, Lenz M, Abagnale G, Joussen S, Denecke B . Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports. 2014; 3(3):414-22. PMC: 4266008. DOI: 10.1016/j.stemcr.2014.07.003. View

Cheng F, Guo D . MET in glioma: signaling pathways and targeted therapies. J Exp Clin Cancer Res. 2019; 38(1):270. PMC: 6585013. DOI: 10.1186/s13046-019-1269-x. View

de Cassia Noronha N, Mizukami A, Caliari-Oliveira C, Cominal J, Rocha J, Covas D . Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019; 10(1):131. PMC: 6498654. DOI: 10.1186/s13287-019-1224-y. View

Costello B, Shah G, Kumta P, Sfeir C . Regenerative medicine for craniomaxillofacial surgery. Oral Maxillofac Surg Clin North Am. 2010; 22(1):33-42. DOI: 10.1016/j.coms.2009.10.009. View

Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4):581-611. DOI: 10.1210/er.2003-0027. View

Wobma H, Tamargo M, Goeta S, Brown L, Duran-Struuck R, Vunjak-Novakovic G . The influence of hypoxia and IFN-γ on the proteome and metabolome of therapeutic mesenchymal stem cells. Biomaterials. 2018; 167:226-234. PMC: 5894357. DOI: 10.1016/j.biomaterials.2018.03.027. View

Liu Y, Han Z, Zhang S, Jing Y, Bu X, Wang C . Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem. 2011; 286(28):25007-15. PMC: 3137074. DOI: 10.1074/jbc.M110.213108. View

Fernandez C, Moses M . Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun. 2006; 345(1):523-9. DOI: 10.1016/j.bbrc.2006.04.083. View

Kaga T, Kawano H, Sakaguchi M, Nakazawa T, Taniyama Y, Morishita R . Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol. 2012; 57(1):3-9. DOI: 10.1016/j.vph.2012.02.002. View

10.

Kong D, Kim Y, Kim M, Jang J, Lee S . Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int J Mol Sci. 2018; 19(4). PMC: 5979609. DOI: 10.3390/ijms19041057. View

11.

Yang A, Lu Y, Xing J, Li Z, Yin X, Dou C . IL-8 Enhances Therapeutic Effects of BMSCs on Bone Regeneration via CXCR2-Mediated PI3k/Akt Signaling Pathway. Cell Physiol Biochem. 2018; 48(1):361-370. DOI: 10.1159/000491742. View

12.

Sakkas A, Wilde F, Heufelder M, Winter K, Schramm A . Autogenous bone grafts in oral implantology-is it still a "gold standard"? A consecutive review of 279 patients with 456 clinical procedures. Int J Implant Dent. 2017; 3(1):23. PMC: 5453915. DOI: 10.1186/s40729-017-0084-4. View

13.

Kehl D, Generali M, Mallone A, Heller M, Uldry A, Cheng P . Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. NPJ Regen Med. 2019; 4:8. PMC: 6467904. DOI: 10.1038/s41536-019-0070-y. View

14.

Maumus M, Jorgensen C, Noel D . Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. Biochimie. 2013; 95(12):2229-34. DOI: 10.1016/j.biochi.2013.04.017. View

15.

Ng J, Hynes K, White G, Sivanathan K, Vandyke K, Bartold P . Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells. J Cell Biochem. 2016; 117(12):2844-2853. DOI: 10.1002/jcb.25596. View

16.

Caplan A, Correa D . The MSC: an injury drugstore. Cell Stem Cell. 2011; 9(1):11-5. PMC: 3144500. DOI: 10.1016/j.stem.2011.06.008. View

17.

Kwon H, Hur S, Park K, Kim C, Kim Y, Kim H . Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis. Vascul Pharmacol. 2014; 63(1):19-28. DOI: 10.1016/j.vph.2014.06.004. View

18.

Murphy M, Moncivais K, Caplan A . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013; 45:e54. PMC: 3849579. DOI: 10.1038/emm.2013.94. View

19.

Heidemann J, Ogawa H, Dwinell M, Rafiee P, Maaser C, Gockel H . Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem. 2002; 278(10):8508-15. DOI: 10.1074/jbc.M208231200. View

20.

Umrath F, Weber M, Reinert S, Wendel H, Avci-Adali M, Alexander D . iPSC-Derived MSCs Versus Originating Jaw Periosteal Cells: Comparison of Resulting Phenotype and Stem Cell Potential. Int J Mol Sci. 2020; 21(2). PMC: 7013802. DOI: 10.3390/ijms21020587. View